Digene Gel is an over-the-counter antacid medication used to relieve symptoms associated with acidity, heartburn, and indigestion. This type of antacid is taken orally and works by neutralizing excess ...

Deal consolidates firms’ technology in molecular diagnostics. Qiagen and Digene entered into a definitive agreement to combine the two companies to create market and technology leadership in molecular ...

QIAGEN N.V. has announced the successful completion of its acquisition of Digene Corporation. QIAGEN completed the acquisition through a tender offer and subsequent merger of Digene with and into a ...

When federal regulators last week approved Digene Corp.'s cervical cancer test as a primary screening tool for women over 30, they catapulted what had been a follow-up test into direct competition ...

Shares of Digene, a maker of DNA and RNA tests, sizzled on Monday after it announced that Netherlands-based Qiagen would purchase the company in a $1.6 billion deal. Digene is best known for a test to ...

Marissa Jaret Winokur‘s journey to motherhood is not typical and she wants to make sure that yours doesn’t go the same way. In 2000, at the age of 27, just as her Broadway career was starting to ...

The Drugs Control General of India (DCGI) has issued an advisory alert against Abbott’s antacid Digene gel. The regulator has asked patients to discontinue the use of Digene Gel manufactured at the ...

Digene Corp. announced yesterday that Daryl J. Faulkner, a biotech industry veteran, will take over as chief executive next month. Faulkner replaces the Gaithersburg company’s current CEO, Evan L.

correctionThe name of Joe Simons, director of the Federal Trade Commission's Bureau of Competition, was misspelled in a June 25 Business article. (Published 6/26/02) The Federal Trade Commission voted ...

The diagnostic firm Digene Corp. is raising $56 million in gross proceeds by way of a public offering announced after Wednesday's market close. Management at the Gaithersburg, Md.-based company ...

<TAB>Digene Corp. has settled a licensing dispute with Georgetown University that threatened to snatch away a key part of its cervical cancer screening tests, the company said ...